BUSINESS MODEL
NAUGEN envisions to be a global innovation hub to incubate
multiple innovative portfolio companies or Special Purpose Companies (SPCs).
Special Purpose Companies
SPCs are NAUGEN’s portfolio companies created to develop and commercialize specific assets and/or technologies.
Each SPC operates as an independent entity, and NAUGEN provides each SPC with strategy, business development, and investor relations services in exchange for equity and/or service-based revenue.
NAUGEN works closely with strategic partners and investors to facilitate investment into the SPCs.
NAUGEN and Associate Companies
NAUGEN collaborates closely with selected strategic collaborators and an advisory group with top-tier global expertise across key functional areas.
Strategic collaborators include the ones with expertise of strategy & planning, business development, investment relations, intellectual property, legal affairs, science, research & development, clinical development & regulatory affairs, etc.
KEY OBJECTIVE
NAUGEN dreams and works together with pioneering founders and inventors by creating a comprehensive strategy to accelerate establishment, funding, growth and monetization of innovative special purpose companies (SPCs) under its umbrella in a global perspective.
NAUGEN aims to grow its SPCs as globally reputable and influential companies that make a significant difference for people in need across the world.
VALUE PROPOSITION
We drive an accelerated growth.
Identify innovative high-potential projects at a very early stage or before clinical PoC, while their potential value has not been recognized by the market.
In-license or merge & acquire synergistic components from multiple entities across the world and have them converge into an optimal vessel (SPC).
Implement a pivotal strategy & development plan to accelerate an exponential growth of the value.
OPTION Of GROWTH And EXIT
We will help implement various business development strategies for SPCs’ successful funding, growth and monetization at the earliest right timing.
GLOBAL NETWORK
With the headqaurters at Washington DC Metro Area in the US, we connect with inventors and collaborators worldwide leveraging our global network with strategic regions such as Korea, Japan, etc., where innovations dynamically arise.
-
Biopharma ecosystem - NIH, FDA, etc.
-
Approachability to New York and Boston
-
Favorable living condition
-
Favorable human resources environment
-
In-depth and creative science
-
The world-class bio/pharmaceutical ecosystem
-
Asian connection to China and Japan
-
Home of dynamic biotech innovation
-
Excellent clinical trial environment